Epcoritamab and Rituximab for First-line Follicular Lymphoma
NCT ID: NCT05783609
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
100 participants
INTERVENTIONAL
2023-06-21
2030-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The names of the study drugs involved in this study are:
* Rituximab (a type of monoclonal antibody therapy)
* Epcoritamab (a T-cell bispecific antibody)
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The U.S. Food and Drug Administration (FDA) has not approved epcoritamab as a treatment for any disease.
The U.S. Food and Drug Administration (FDA) has approved rituximab as a treatment option for follicular lymphoma (FL).
The research study procedures include screening for eligibility, study treatment with evaluations, blood tests, bone marrow biopsies, and Computerized Tomography (CT) scans and Positron Emission Tomography (PET) scans.
Participants will receive study treatment for approximately 9-10 months and will be followed for up to 10 years.
It is expected that about 100 people will take part in this research study, 35 participants in the initial cohort and 65 patients in the expansion cohort.
Genmab and AbbVie are supporting this research study by providing one of the study drugs, Epcoritamab. Genmab is providing funding for the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Epcoritamab + Rituximab
Participants will undergo study procedures as outlined:
* PET/CT scans at baseline and after cycles 2, 5, and 9 of treatment.
* Cycle 1:
* Days -14, -7, 1, 8 of 6 week cycle: Predetermined dose of Rituximab.
* Days 1, 8, 15, 22 of 6 week cycle: Predetermined dose of Epcoritamab. (Day 15 of Epcoritamab dosage will be administered in the hospital.)
* Cycles 2 - 3:
--Days 1, 8, 15, 22 of 4 week cycle: Predetermined dose of Epcoritamab.
* Cycles 4 - 9:
* Day 1 of 4 week cycle: Predetermined dose of Epcoritamab.
* Day 15 of 4 week cycle: Predetermined dose of Epcoritamab.
* Surveillance imaging (PT/CT scans) at months 13, 18, and 24 after initiation of treatment.
* Follow up visits for up to 5 years.
Epcoritamab
T-cell bispecific antibody, via subcutaneous injection
Rituximab
Chimeric anti-CD20 monoclonal antibody, via IV infusion
Epcoritamab + Rituximab Expansion
Participants will undergo study procedures as outlined:
* PET/CT scans at baseline and after cycles 2, 5, and 9 of treatment.
* Cycle 1:
* Days -14, -7, 1, 8 of 6 week cycle: Predetermined dose of Rituximab.
* Days 1, 8, 15, 22 of 6 week cycle: Predetermined dose of Epcoritamab.
* Cycles 2 - 3:
--Days 1, 8, 15, 22 of 4 week cycle: Predetermined dose of Epcoritamab.
* Cycles 4 - 9:
* Day 1 of 4 week cycle: Predetermined dose of Epcoritamab.
* Surveillance imaging (PT/CT scans) at months 13, 18, and 24 after initiation of treatment.
* Follow up visits for up to 5 years.
Epcoritamab
T-cell bispecific antibody, via subcutaneous injection
Rituximab
Chimeric anti-CD20 monoclonal antibody, via IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Epcoritamab
T-cell bispecific antibody, via subcutaneous injection
Rituximab
Chimeric anti-CD20 monoclonal antibody, via IV infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No prior systemic therapy for FL. Prior treatment with radiation therapy or short course steroids is allowed.
* Meets at least one criterion to begin treatment based on the modified GELF (Groupe d'Etude des Lymphomes Folliculaires) criteria:
* Symptomatic adenopathy
* Organ function impairment due to disease involvement, including cytopenias due to marrow involvement (WBC \<1.5x109/L; absolute neutrophil count \[ANC\] \<1.0x109/L, Hgb \<10g/dL; or platelets \<100x109/L)
* Constitutional symptoms (defined as persistent fevers \>100.4 F, shaking chills, drenching night sweats, or loss of \>10% of body weight within a 6 month period)
* Any nodal or extranodal tumor mass \>7 cm in maximum diameter
* \>3 nodal sites of involvement \>3 cm
* Local compressive symptoms or imminent risk thereof
* Splenomegaly (craniocaudal diameter \> 16cm on CT imaging)
* Clinically significant pleural or peritoneal effusion
* Leukemic phase (\>5x109/L circulating malignant cells)
* Rapid generalized disease progression
* Renal infiltration
* Bone lesions
* Patients cannot be in need of urgent cytoreductive chemotherapy (in the opinion of the treating investigator).
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. (Appendix A)
* Age ≥18 years.
* Adequate hematologic and organ function:
1. Absolute neutrophil count \> 1.0x109/L unless due to marrow involvement by lymphoma in which case ANC must be \>0.5x109/L
2. Platelets \> 75 x109/L, unless due to marrow involvement by lymphoma, in which case platelets must be \>50 x109/L
3. Estimated CrCl (Cockcroft Gault) ≥ 45ml/min
4. Total bilirubin \< 1.5 X ULN, unless Gilbert syndrome, in which case direct bilirubin must be \< 1.5 x ULN
5. AST/ALT \< 2.5 X ULN, unless documented liver involvement by lymphoma, in which case AST/ALT must be \<5 x ULN
* Ability to understand and the willingness to sign a written informed consent document.
* Willingness to provide a pre-treatment tumor sample by core needle or excisional surgical biopsy. A fresh biopsy is strongly encouraged, but an archival sample is acceptable if the following provisions are met: 1) availability of a tumor-containing formalin-fixed, paraffin-embedded (FFPE) tissue block, 2) if the tumor containing FFPE tissue block cannot be provided in total, sections from this block should be provided that are freshly cut and mounted on positively-charged glass slides. Preferably, 25 slides should be provided; if not possible, a minimum of 15 slides is required. Exceptions to this criterion may be made with approval of the Sponsor-Investigator.
* Willingness to remain abstinent or to use two effective contraceptive methods that result in a failure rate of \<1% per year from screening until: (a) at least 3 months after pre-treatment with rituximab or 12 months after the last dose of epcoritamab, whichever is longer, if the patient is a male or (b) until at least 18 months after pre-treatment with rituximab or 12 months after the last dose of epcoritamab, whichever is longer, if patient is a female. Examples of contraceptive methods with a failure rate of \<1% per year include:
* Tubal ligation, male sterilization, hormonal implants, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
* Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of \<1% per year. Barrier methods must always be supplemented with the use of a spermicide.
Exclusion Criteria
* Patients with bulky cervical adenopathy that is compressing the upper airway or could result in significant airway compression during a tumor flare event.
* Patients with stage I follicular lymphoma
* Patients who are candidates for radiation therapy with curative intent (in the opinion of the treating investigator)
* Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia).
* Active HBV (DNA PCR-positive) or hepatitis C (RNA PCR-positive infection). Subjects with evidence of prior HBV but who are PCR-negative are permitted in the trial but should receive prophylactic antiviral therapy. Subjects who received treatment for HCV that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable.
* Known history of seropositivity for human immunodeficiency virus (HIV). Note: HIV testing is required at screening only if required per local health authorities or institutional standards.
* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at trial enrolment or significant infections within 2 weeks prior to the first dose of epcoritamab.
* Prior history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least 2 years.
* Patients should not have received immunization with attenuated live vaccine within one week of study entry or during study period.
* Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study or limit adherence to study requirements.
* Patients with any one of the following currently on or in the previous 6 months will be excluded: myocardial infarction, congenital long QT syndrome, torsade de pointes, unstable angina, coronary/peripheral artery bypass graft, cardiac arrhythmia (CTCAE grade 3 or higher), clinically significant ECG abnormalities, or cerebrovascular accident.
* Patients with New York Heart Association Class III or IV heart failure or known ejection fraction of \<45%.
* Inability to comply with protocol mandated hospitalizations and restrictions.
* Patients who are pregnant, breast-feeding, or intending to become pregnant during the study.
* Prior solid organ or allogeneic stem cell transplantation.
* History of known or suspected hemophagocytic lymphohistiocytosis (HLH).
* History of autoimmune disease, including but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
• Patients with a remote history of, or well controlled, autoimmune disease who meet above criteria may be eligible to enroll after consultation with the Sponsor-Investigator.
* History of severe allergic or anaphylactic reactions to anti-CD20 mAb therapy or known allergy or intolerance to any component or excipient of epcoritamab.
* Vaccination with live vaccines within 28 days prior to the first dose of epcoritamab.
* Active CNS lymphoma
* Neuropathy \> grade 2. (CTCAE)
* Treatment with CAR-T therapy within 100 days prior to first dose of epcoritamab.
* Treatment with an investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to the first dose of epcoritamab.
* Chemotherapy and other non-investigational anti-neoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose of epcoritamab.
* No known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. If a subject has signs/symptoms suggestive of SARS-CoV-2 infection or had recent known exposure to someone with SARS-CoV-2 infection, the subject must have a negative molecular (e.g., PCR) test, or 2 negative antigen test results at least 24 hours apart, to rule out SARS-CoV-2 infection. Subjects who do not meet SARS-CoV-2 infection eligibility criteria will be screen failed and may only rescreen after they meet the following SARS-CoV-2 infection viral clearance criteria:
* No signs/symptoms suggestive of active SARS-CoV-2 infection
* Negative molecular (e.g., PCR) result or 2 negative antigen test results at least 24 hours apart
* Screening 12-lead ECG showing a baseline QTcF \>470 msec.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genmab
INDUSTRY
AbbVie
INDUSTRY
Reid Merryman, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Reid Merryman, MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Reid Merryman, MD
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of Rochester Medical Center
Rochester, New York, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gottfried von Keudell, MD
Role: primary
Reid W Merryman, MD
Role: primary
Danielle Wallace, MD
Role: primary
Yazeed Sawalha, MD
Role: primary
Esta Konkol
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-702
Identifier Type: -
Identifier Source: org_study_id